GSK punts a failed cardio drug to a biotech startup — which has a new development strategy in mind
More than 3 years after losmapimod proved to be a turkey in a late-stage cardio study at GlaxoSmithKline, the drug has been dusted off and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
